Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:36:18.407Z.
Calculation as of: 2026-10-06T13:36:18.407Z.
Quote observation: 2026-10-06T13:35:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Definium Therapeutics, Inc.
Market Cap
$4.77B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.78B
Price/FCF Ratio
27.48
TTM Avg
23.99
3Y Avg
32.53
5Y Avg
32.53
Market Cap
$4.89B
Price/FCF Ratio
N/A
TTM Avg
18.04
3Y Avg
18.04
5Y Avg
18.04
Market Cap
$4.61B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.93B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.47B
Price/FCF Ratio
N/A
TTM Avg
30.17
3Y Avg
53.50
5Y Avg
47.42
Market Cap
$5.08B
Price/FCF Ratio
153.03
TTM Avg
194.41
3Y Avg
194.41
5Y Avg
194.41
Market Cap
$4.36B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.77B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.78B | 27.48 | 23.99 | 32.53 | 32.53 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.89B | N/A | 18.04 | 18.04 | 18.04 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.61B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.93B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.47B | N/A | 30.17 | 53.50 | 47.42 |
| BillionToOne, Inc. (BLLN)vs › | $5.08B | 153.03 | 194.41 | 194.41 | 194.41 |
| Erasca, Inc. (ERAS)vs › | $5.11B | N/A | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.36B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.29B | 25.98 | 26.02 | 39.55 | 43.37 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
